Ensysce Biosciences, Inc.
ENSC
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioiā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.16
Price+1.76%
$0.02
1Y
Price
Market Cap
$2.750m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+3.7%
EBITDA Margin-756.3%
Net Profit Margin-403.5%
Free Cash Flow MarginRevenue
$4.488m
-13.8%
1y CAGR+36.0%
3y CAGR+19.9%
5y CAGREarnings
-$10.973m
-37.4%
1y CAGR+14.5%
3y CAGR+15.1%
5y CAGREPS
-$6.37
-39.4%
1y CAGR+19.9%
3y CAGR+30.2%
5y CAGRBook Value
$874.710k
$3.179m
Assets$2.305m
Liabilities$364.070k
DebtDebt to Assets
11.5%
-0.2x
Debt to EBITDAFree Cash Flow
-$7.168m
+100.0%
1y CAGR-23199406.5%
3y CAGR-17399584.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company